MX2007015848A - Variantes geneticas en el gen tcf7l2 como marcadores de diagnostico para el riesgo de diabetes mellitus tipo 2. - Google Patents

Variantes geneticas en el gen tcf7l2 como marcadores de diagnostico para el riesgo de diabetes mellitus tipo 2.

Info

Publication number
MX2007015848A
MX2007015848A MX2007015848A MX2007015848A MX2007015848A MX 2007015848 A MX2007015848 A MX 2007015848A MX 2007015848 A MX2007015848 A MX 2007015848A MX 2007015848 A MX2007015848 A MX 2007015848A MX 2007015848 A MX2007015848 A MX 2007015848A
Authority
MX
Mexico
Prior art keywords
type
risk
diabetes mellitus
genetic variants
diagnostic markers
Prior art date
Application number
MX2007015848A
Other languages
English (en)
Spanish (es)
Inventor
Struan F A Grant
Original Assignee
Decode Genetics Ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decode Genetics Ehf filed Critical Decode Genetics Ehf
Publication of MX2007015848A publication Critical patent/MX2007015848A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MX2007015848A 2005-06-20 2006-06-16 Variantes geneticas en el gen tcf7l2 como marcadores de diagnostico para el riesgo de diabetes mellitus tipo 2. MX2007015848A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69217405P 2005-06-20 2005-06-20
US75715506P 2006-01-06 2006-01-06
PCT/IS2006/000014 WO2006137085A1 (en) 2005-06-20 2006-06-16 Genetic variants in the tcf7l2 gene as diagnostic markers for risk of type 2 diabetes mellitus

Publications (1)

Publication Number Publication Date
MX2007015848A true MX2007015848A (es) 2008-04-22

Family

ID=37036993

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007015848A MX2007015848A (es) 2005-06-20 2006-06-16 Variantes geneticas en el gen tcf7l2 como marcadores de diagnostico para el riesgo de diabetes mellitus tipo 2.

Country Status (14)

Country Link
US (3) US7585630B2 (https=)
EP (1) EP1907569B1 (https=)
JP (1) JP5301987B2 (https=)
KR (1) KR101374304B1 (https=)
CN (1) CN101238222B (https=)
AU (1) AU2006260477B2 (https=)
BR (1) BRPI0612301A2 (https=)
CA (1) CA2612475C (https=)
EA (1) EA016397B1 (https=)
IL (1) IL188147A (https=)
MX (1) MX2007015848A (https=)
NO (1) NO341910B1 (https=)
NZ (1) NZ564285A (https=)
WO (1) WO2006137085A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
JP5301987B2 (ja) * 2005-06-20 2013-09-25 デコード・ジェネティクス・イーエイチエフ ２型糖尿病のリスクの診断マーカーとしてのｔｃｆ７ｌ２遺伝子中の遺伝子変異体
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2540725A1 (de) 2006-05-04 2013-01-02 Boehringer Ingelheim International GmbH Polymorphe von 1-((4-Methyl-chinazolin-2-yl)methyl)-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthin
SG177148A1 (en) * 2006-11-30 2012-01-30 Decode Genetics Ehf Genetic susceptibility variants of type 2 diabetes mellitus
WO2008109079A2 (en) * 2007-03-01 2008-09-12 Novetide, Ltd. High purity peptides
CA2685816A1 (en) * 2007-04-30 2008-11-06 Compugen Ltd. Allelic polymorphism associated with diabetes
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
CN102149407A (zh) 2008-09-10 2011-08-10 贝林格尔.英格海姆国际有限公司 治疗糖尿病和相关病症的组合疗法
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
CN102256976A (zh) 2008-12-23 2011-11-23 贝林格尔.英格海姆国际有限公司 有机化合物的盐形式
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
AU2010269841A1 (en) 2009-07-10 2012-02-23 Decode Genetics Ehf Genetic markers associated with risk of diabetes mellitus
KR20240090632A (ko) * 2009-11-27 2024-06-21 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
WO2011161161A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Diabetes therapy
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
US8883800B2 (en) 2011-07-15 2014-11-11 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
JP6218811B2 (ja) 2012-05-14 2017-10-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US20160077079A1 (en) * 2013-03-14 2016-03-17 The Children's Hospital Of Philadelphia The children's hospital of philadelphia
RU2521202C1 (ru) * 2013-04-12 2014-06-27 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" Способ прогнозирования риска развития сахарного диабета второго типа у больных гипертонической болезнью
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
CN103882127B (zh) * 2014-03-13 2016-03-16 河北联合大学 用于预测患2型糖尿病肾病发生风险的试剂盒
WO2016201438A1 (en) * 2015-06-11 2016-12-15 The Children's Hospital Of Philadelphia New targets modulated by a casual variant of type 2 diabetes (t2d) embedded within the tcf7l2 gene and methods of use thereof for identifying agents having efficacy for the treatment of type 2 diabetes and other metabolic disorders
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
CN109182508A (zh) * 2018-10-22 2019-01-11 北京华夏时代生物工程有限公司 Tcf7l2基因单核苷酸多态性的荧光原位杂交测序方法
TWI702292B (zh) * 2018-12-28 2020-08-21 薩摩亞商康多富國際有限公司 個人化新陳代謝疾病保健食品組合的決定方法及非暫態電腦可讀取儲存媒體

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US5288611A (en) * 1983-01-10 1994-02-22 Gen-Probe Incorporated Method for detecting, identifying, and quantitating organisms and viruses
ATE202801T1 (de) * 1983-01-10 2001-07-15 Gen Probe Inc Verfahren zum nachweis, identifizieren und quantifizieren von organismen und viren
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
DE3534934A1 (de) * 1985-10-01 1987-04-02 Draegerwerk Ag Kolorimetrisches gasdosimeter
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5176996A (en) * 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) * 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5424186A (en) * 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5264564A (en) * 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5384261A (en) * 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
US5858659A (en) * 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5837832A (en) * 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US6057117A (en) 1996-04-04 2000-05-02 Chiron Corporation Identification and use of selective inhibitors of glycogen synthase kinase 3
WO1998016528A1 (en) 1996-10-11 1998-04-23 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
WO1999065897A1 (en) 1998-06-19 1999-12-23 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US6512102B1 (en) 1998-12-31 2003-01-28 Chiron Corporation Compositions and methods of diagnosis and treatment using casein kinase I
CN100335479C (zh) 1999-12-17 2007-09-05 希龙公司 糖元合成酶激酶3的双环抑制剂
JP2003516974A (ja) 1999-12-17 2003-05-20 カイロン コーポレイション グリコーゲンシンターゼキナーゼ３のピラジンベースインヒビター
ES2295191T3 (es) 2000-07-27 2008-04-16 Novartis Vaccines And Diagnostics, Inc. Polipeptidos de gsk3.
AU785425B2 (en) * 2001-03-30 2007-05-17 Genetic Technologies Limited Methods of genomic analysis
US7064215B2 (en) 2001-07-03 2006-06-20 Chiron Corporation Indazole benzimidazole compounds
WO2003014143A2 (en) * 2001-08-04 2003-02-20 Whitehead Institute For Biomedical Research Haplotype map of the human genome and uses therefor
WO2003024447A1 (en) 2001-09-20 2003-03-27 Smithkline Beecham Corporation Inhibitors of glycogen synthase kinase-3
US20040072831A1 (en) 2001-10-12 2004-04-15 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US20040023237A1 (en) * 2001-11-26 2004-02-05 Perelegen Sciences Inc. Methods for genomic analysis
US6762185B1 (en) 2002-03-01 2004-07-13 Choongwae Pharma Corporation Compounds useful for treatment of cancer, compositions containing the same, and methods of their use
EP1380644A1 (en) 2002-07-08 2004-01-14 Kylix B.V. The use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role
EP1539754A4 (en) 2002-08-23 2009-02-25 Novartis Vaccines & Diagnostic BENZIMIDAZOCHINOLINONE AND ITS USE
WO2004032838A2 (en) 2002-10-04 2004-04-22 The Regents Of The University Of California Methods for treating cancer by inhibiting wnt signaling
CA2501514A1 (en) * 2002-11-01 2004-05-21 Decode Genetics Ehf. Human type ii diabetes gene-slit-3 located on chromosome 5q35
US20040146870A1 (en) * 2003-01-27 2004-07-29 Guochun Liao Systems and methods for predicting specific genetic loci that affect phenotypic traits
CN1548553A (zh) * 2003-05-21 2004-11-24 中国医学科学院基础医学研究所 用于预测2型糖尿病易感性的试剂盒及引物
US6991110B2 (en) * 2003-07-02 2006-01-31 Inficon, Inc. Package for storing sensor crystals and related method of use
CA2537099A1 (en) 2003-08-28 2005-03-10 Choongwae Pharma Corporation Modulation of .beta.-catenin/tcf activated transcription
JP5301987B2 (ja) * 2005-06-20 2013-09-25 デコード・ジェネティクス・イーエイチエフ ２型糖尿病のリスクの診断マーカーとしてのｔｃｆ７ｌ２遺伝子中の遺伝子変異体

Also Published As

Publication number Publication date
NZ564285A (en) 2010-03-26
KR20080051128A (ko) 2008-06-10
CN101238222B (zh) 2013-04-10
CN101238222A (zh) 2008-08-06
US20090275043A1 (en) 2009-11-05
NO20080389L (no) 2008-01-21
EP1907569A1 (en) 2008-04-09
KR101374304B1 (ko) 2014-03-14
BRPI0612301A2 (pt) 2009-01-27
AU2006260477B2 (en) 2012-02-23
JP2008546403A (ja) 2008-12-25
CA2612475A1 (en) 2006-12-28
HK1117569A1 (en) 2009-01-16
NO341910B1 (no) 2018-02-19
EA016397B1 (ru) 2012-04-30
CA2612475C (en) 2015-07-28
EA200800087A1 (ru) 2008-06-30
WO2006137085A1 (en) 2006-12-28
US7585630B2 (en) 2009-09-08
EP1907569B1 (en) 2013-04-10
US20120149016A1 (en) 2012-06-14
US20060286588A1 (en) 2006-12-21
IL188147A0 (en) 2008-03-20
AU2006260477A8 (en) 2006-12-28
AU2006260477A1 (en) 2006-12-28
IL188147A (en) 2013-02-28
JP5301987B2 (ja) 2013-09-25

Similar Documents

Publication Publication Date Title
MX2007015848A (es) Variantes geneticas en el gen tcf7l2 como marcadores de diagnostico para el riesgo de diabetes mellitus tipo 2.
EP2527466A3 (en) Genetic variants on CHR2 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
IL249715B (en) N-butyl-deoxynojirimycin for use as a drug for the treatment of Pompe disease in combination with an enzyme replacement therapy agent
WO2007131072A3 (en) Hydrolytically-resistant boron-containing therapeutics and methods of use
WO2008103470A3 (en) Oncogenic-ras-signal dependent lethal compounds
MX2009005849A (es) Composiciones y metodos para tratar cancer con adn rico en cpg y cupredoxinas.
ATE528300T1 (de) Bizyklische verbindungen und ihre verwendung als antidiabetika
WO2009038689A3 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
WO2011001135A3 (en) Diagnosis and treatment of alzheimer's disease
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
WO2009059318A3 (en) Genes and polymorphisms associated with amd
WO2007149798A3 (en) Biomarkers for the progression of alzheimer's disease
WO2006063704A3 (en) Single nucleotide polymorphism (snp) associated to type ii diabetes
WO2007044413A3 (en) Wwox gene, vectors containing the same, and uses in treatment of cancer
WO2009036100A3 (en) Prediction of qt prolongation based on snp genotype
WO2007095185A3 (en) Variants in complement regulatory genes predict age-related macular degeneration
WO2008112898A3 (en) Genetic alterations on chromosome 12 and methods of use thereof for the diagnosis and treatment of type 1 diabetes
WO2008065682A3 (en) Genetic susceptibility variants of type 2 diabetes mellitus
WO2007120955A3 (en) Genes affecting human memory performance
PL1730315T3 (pl) Polimorfizmy w genie NOD2/CARD15
WO2006099259A3 (en) Novel missense mutations and single nucleotide polymorphisms in the rabphillin-3a-like gene and uses thereof
WO2010008858A8 (en) Use of iron-related pathways and genes for treatment and diagnosis of parkinson's disease
WO2008081447A3 (en) Compounds and methods for detection of cells
WO2010011626A3 (en) Pyridinyl modulators of ϒ-secretase

Legal Events

Date Code Title Description
FG Grant or registration